Abstract
The characteristic feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19 disease) is that its course is asymptomatic or mild in the majority of cases, while increasing age and/or underlying cardiovascular diseases predispose for a severalfold increased case fatality rate. 1 This association has not been explained as yet, and several potential mechanisms have been put forward to uncover why the course of the disease is more severe in elderly patients with underlying cardiovascular risk factors and/or cardiovascular diseases. Some hypotheses have been proposed, including the role of angiotensin-converting enzyme 2 (ACE2) (a functional receptor for SARS-CoV-2), accelerated ageing of the immune system, or other mechanisms linked to comorbidities. 1 However, it has been recently reported that SARS-CoV-2 virus-induced endotheliitis and microvascular endothelium pathology could contribute to vascular bed dysfunction in different organs and to fatal clinical sequelae in COVID-19 patients. 2 Indeed, in patients who died from COVID-19, severe endothelial injury, widespread thrombosis, and microangiopathy were detected, 3 pointing to the important role of vascular pathophysiology and alterations in endothelial function in COVID-19 disease. In fact, a biomarker of endothelial activation and altered endothelial permeability, angiopoietin-2, was found to be a good predictive factor for severe cases of COVID-19 4 disease underscoring important pathophysiological role of vascular endothelial dysfunction in COVID-19, with its distinct vascular endotype. 5
Funding Information
  • FNP (TEAM POIR.04.04.00-00-5CAC/17-00, SYMFONIA NCN, DEC-2015/16/W/NZ4/00070)
  • NCN (2018/29/B/NZ7/01684, STRATEGMED1/233226/11/NCBR/2015)

This publication has 17 references indexed in Scilit: